[422 Pages Report] The global vascular endothelial growth factor inhibitors market is expected to be worth US$ 22.7 billion by the end of 2022, and to grow at a CAGR of 4.0% to be worth US$ 33.5 billion by 2032. According to a recent study by Future Market Insights, biologics are leading the market as drugs, with …
Author Archives: Editor AN
Hyaluronic Acid Products Market exhibiting growth at 6.1% CAGR through 2030
[284 Pages Report] Hyaluronic acid products have been gaining the momentum backed by massive use in therapies intended at the treatment of osteoarthritis, vesicoureteral reflux (VUR), and dry eye diseases, besides diverse aesthetic applications. Future Market Insights (FMI) in a new study has forecast the global market for hyaluronic acid products to surpass US$ 2.7 Bn by 2021. …
Continue reading “Hyaluronic Acid Products Market exhibiting growth at 6.1% CAGR through 2030”
Hyperglycemia Treatment Market to grow at a 12.3% CAGR from 2023 to 2033, Insulin Therapy to be Most Common Treatment Approach: FMI Report
According to Future Market Insights, the global hyperglycemia treatment is expected to grow at a CAGR of 12.3% between 2023 and 2033, reaching US$ 1,596 Million in 2033. With the growing number of young people prone to stress levels and poor eating habits, hyperglycemia treatments have become more popular. According to a new study, COVID-19 …
Hyperammonemia Treatment Market to reach US$ 2,100 Million by 2033, glycerol phenylbutyrate to account for over 1/3rd of all Treatments: FMI
According to a recently published study by Future Market Insights, the global hyperammonemia treatment market size is expected to reach a valuation of US$ 1,318.05 Million in 2023 and is projected to reach US$ 2,100 Million by 2033, trailing a CAGR of 4.77%. The rising prevalence of urea cycle disorders and extensive research and development …
Research and Development for Hutchinson Gilford progeria syndrome (HGPS) Therapeutics to Register 8.5% CAGR: FMI Study
During the forecast period 2023-2033, the Hutchinson Gilford progeria syndrome (HGPS) Therapeutics market is expected to grow at a value of 8.5% CAGR, according to Future Market Insights. By the year 2033, the global market for Hutchinson Gilford progeria syndrome is expected to rise up to a market valuation of US$ 15,990 Million. Around 400 …
Intestinal Fistula Treatment Market Value to reach US$ 46.82 Billion by 2033; Proton-Pump Inhibitor Drugs to account for 45% of all Treatments: FMI Report
The global intestinal fistula treatment market is expected to be valued at US$ 26.64 Billion in 2023. With the continuous improvements in drugs and biotechnology, the overall demand for intestinal fistula treatment is projected to grow at a CAGR of 5.8% between 2023 and 2033, totaling around US$ 46.82 Billion by 2033. Factors such as …
Increasing Prevalence of Hormonal Problems to Propel the Growth in the Market for Hypopituitarism Diagnostics at 6% CAGR: FMI Study
The global Hypopituitarism Diagnostics Market is expected to garner a market value of US$ 250 Million in 2023 and is expected to accumulate a market value of US$ 447.41 Million by registering a CAGR of 6% in the forecast period 2023-2033. The market for Hypopituitarism Diagnostics registered a CAGR of 4% in the historical period …
Takotsubo Syndrome Therapeutics Market to reach US$ 2.85 Billion by 2033; growing at a CAGR of 6.1%: FMI Report
The global takotsubo syndrome therapeutics market is predicted to exceed an impressive valuation of US$ 2.85 Billion in 2033, with a compound annual growth rate (CAGR) of 6.1% estimated from 2023 to 2033. In both industrialized and developing economies, cardiovascular diseases are the leading cause of death. The rising prevalence of cardiovascular problems such as …
Rising Focus of Government Organizations to Propel the Growth in the Market for Congenital Hyperinsulinism Treatment at 6% CAGR: FMI Study
The global Congenital Hyperinsulinism Treatment Market is expected to garner a market value of US$ 100 Million in 2023 and is expected to accumulate a market value of US$ 179.08 Million by registering a CAGR of6% in the forecast period 2023-2033. The market for Congenital Hyperinsulinism registered a CAGR of 4% in the historical period …
Andersen Tawil Syndrome Treatment Market to reach US$ 4.2 Billion by 2033; Type-1 Treatment to comprise 59% of all Procedures: FMI Report
As per a recently published study by Future Market Insights, the global Andersen Tawil syndrome treatment market is expected to surpass an impressive valuation of US$ 1.9 Billion in 2023 and is projected to reach US$ 4.2 Billion by 2033, with a CAGR of 8.26%. Rising government assistance, provision of incentives to pharmaceutical companies, increasing …